Euthymics expands series A financing to work on 'next generation Straterra'

Euthymics Bioscience has added $4 million to its series A financing to fund preclinical development of its second product candidate, EB-1020, a non-stimulant for adult attention deficit hyperactivity disorder (ADHD). The product is "a different drug altogether" from Shire's non-stimulant ADHD drug Intuniv (guanfacine), Euthymic's president and CEO, Anthony McKinney, told Scrip.

Euthymics Bioscience has added $4 million to its series A financing to fund preclinical development of its second product candidate, EB-1020, a non-stimulant for adult attention deficit hyperactivity disorder (ADHD). The product is "a different drug altogether" from Shire's non-stimulant ADHD drug Intuniv (guanfacine), Euthymic's president and CEO, Anthony McKinney, told Scrip.

"Members of our leadership team were involved in the development of the first non-stimulant developed for ADHD, Lilly's Straterra (atomoxetine), and we've built on the lessons from that. We have the experience and the network to optimise the development of EB-1020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By 

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By 

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

More from Therapeutic Category

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By 

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.